Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer
- 19 February 2008
- journal article
- research article
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 17 (5), 487-495
- https://doi.org/10.1177/0962280207081860
Abstract
This paper is based on a conference presentation in which several authors presented results from analyses of the same dataset concerning the evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival in advanced colorectal cancer clinical trials. In evaluating a potential surrogate endpoint, there is a hierarchy of information that might usually be considered desirable: 1) a biological rationale for surrogacy, 2) demonstration of the prognostic value of the surrogate endpoint in untreated patients and 3) in treated patients and 4) demonstration across randomized comparisons that differences in the effect of randomized treatments on the surrogate endpoint are associated with the corresponding differences in the effect on the clinical endpoint of interest. Results from analyses that might be used to address the third and four requirements are presented and some of the practical issues that arise in evaluating a surrogate endpoint, which would be relevant to many diseases, are illustrated. Although the results presented should not be seen as a definitive analysis of the value of PFS as a surrogate endpoint, concerns are identified about the potential lack of standardization of the definition of PFS or the frequency of evaluation of disease progression and the high leverage of one study in evaluating the association in addressing the fourth requirement.This publication has 8 references indexed in Scilit:
- Validation in the Case of Two Failure-time EndpointsStatistics for Biology and Health, 2005
- Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-AnalysisJournal of Clinical Oncology, 2004
- Evaluating surrogate endpointsControlled Clinical Trials, 2002
- Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trialsEuropean Journal of Cancer, 2002
- On meta-analytic assessment of surrogate outcomesBiostatistics, 2000
- Meta-analysis for the evaluation of potential surrogate markersStatistics in Medicine, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989